Fig. 3.
Vascular conductance in response to increasing doses (A and B) and area under the curve (AUC; C) of the selective serotonin reuptake inhibitor paroxetine alone (CON; open symbols) and during concurrent nitric oxide (NO) synthase inhibition [NG-nitro-l-arginine methyl ester (l-NAME), filled symbols] in healthy adults [HA, n = 6 (5 women)] and in those with major depressive disorder [MDD, n = 6 (4 women)]. The NO-mediated component of paroxetine-induced vasodilation was reduced in MDD. CVCmax, maximal cutaneous vascular conductance. Data are means ± SE and were analyzed using two-way or three-way repeated-measures ANOVA. *P < 0.05 HA vs. MDD; †P < 0.05 CON vs. l-NAME.